What do recent Polivy (polatuzumab vedotin) trials show for progression-free survival (PFS)?
Based on the provided information, there is not enough detail to determine whether Polivy’s progression-free survival (PFS) results have improved in more recent clinical trials. No trial data (by study name, line of therapy, population, or PFS hazard ratio/median PFS) is included here, so an evidence-backed comparison across “recent” studies isn’t possible.
Which Polivy studies would you need to compare to judge “improvement” in PFS?
To assess whether PFS has improved over time, you’d normally compare Polivy’s PFS outcomes across the most recent trials that report PFS (including the same lymphoma subtype and similar treatment settings). This typically requires:
- Trial identifiers (e.g., name and phase)
- Treatment context (e.g., newly diagnosed vs relapsed/refractory; first line vs later lines)
- End points and reporting format (median PFS vs PFS rate at a timepoint; hazard ratio vs raw curves)
- Key eligibility differences (age, prior therapies, transplant eligibility, disease biology)
Without those specific trial results, you can’t reliably conclude improvement or worsening.
Has PFS improved because of better trial design or different patient risk?
Even if you had multiple PFS readouts, differences in patient baseline risk (and in trial design) can change PFS numbers without any real change attributable to Polivy itself. That’s why the “improvement” question usually hinges on whether later trials show:
- Consistently better PFS vs the relevant control, and
- Similar relative effect sizes (e.g., hazard ratios) rather than just higher absolute PFS medians.
What I can do if you share the trial details (or if you mean a specific one)
If you tell me which “recent clinical trials” you mean (for example, the study names/dates or the exact PFS figures you’ve seen), I can compare the PFS outcomes directly and say whether the results look improved in a clinically meaningful way.
If you paste the PFS values (or links/abstracts) for the trials you’re comparing, I’ll synthesize the trend and note any key differences in populations and endpoints.
Sources
None provided in the question.